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Abstract:  
Background & Aims: Esophageal adenocarcinoma (EAC) prognosis is poor because patients often 
present with advanced disease. Models developed to identify patients at risk for EAC and increase 
early detection have been developed based on data from case–control studies. We analyzed data 
from a prospective study to identify factors available to clinicians that identify individuals with a high 
absolute risk of EAC.  
Methods: We collected data from 355,034 individuals (aged ≥50 years) without a prior history of 
cancer enrolled in the UK Biobank prospective cohort study from 2006 through 2010; clinical data 
were collected through September 2014. We identified demographic, lifestyle, and medical factors, 
measured at baseline, that associated with development of EAC within 5 years using logistic 
regression analysis. We used these data to create a model to identify individuals at risk for EAC. 
Model performance was assessed using area under the receiver operating characteristics curve 
(AUROC), sensitivity, and specificity analyses. 
Results: Within up to 5 years of follow up, 220 individuals developed EAC. Age, sex, smoking, body 
mass index, and history of esophageal conditions or treatments identified individuals who developed 
EAC (AUROC, 0.80; 95% CI, 0.77–0.82). We used these factors to develop a scoring system and 
identified a point cut off that 104,723 individuals (29.5%), including 170 of the 220 cases with EAC, 
were above. The scoring system identified individuals who developed EAC with 77.4% sensitivity and 
70.5% specificity. The 5-year risk of EAC was 0.16% for individuals with scores above the threshold 
and 0.02% for individuals with scores below the threshold. 
Conclusion: We combined data on several well-established risk factors that are available to clinicians 
to develop a system to identify individuals with a higher absolute risk of EAC within 5 years. Studies 
are needed to evaluate the utility of these factors in a multi-stage, triaged, screening program. 
KEY WORDS: BMI, upper gastrointestinal cancer, risk-prediction, esophagus 
Introduction 
The incidence of esophageal adenocarcinoma (EAC) is increasing in Western populations1, and 
prognosis is poor. Overall survival is <20%2. Methods to improve early diagnosis are important3 as the 
poor survival is largely attributable to late clinical presentation with advanced disease 2.  
Endoscopy with biopsies for histological confirmation is the gold-standard method of detecting 
esophageal and gastric cancers4,5. However, population-wide endoscopy screening programmes are 
unlikely to be cost-effective or feasible due to the low incidence of upper gastrointestinal cancers and 
the cost, invasiveness and psychological burden of endoscopy screening6.  
Clinical guidelines suggest that individuals with chronic symptomatic gastro-esophageal reflux disease 
(GERD) should be referred for endoscopy screening to identify Barrett’s esophagus7, a pre-cursor to 
EAC present in 1-2% of the adult population8. Individuals with Barrett’s esophagus are often entered 
into endoscopy surveillance programmes9. Use of GERD as the sole initial triage factor for endoscopy 
is appealing in its simplicity but delays in obtaining endoscopy are common in part due to a lack of 
both specificity, as risk of EAC in individuals with GERD is low10,11, and sensitivity, as a large proportion 
of EAC cases (~40%) never report GERD symptoms11.  
Automated clinical risk prediction tools using data easily accessible to primary care physicians, to flag 
high-risk individuals may offer a lower cost method to improve early detection and are being 
investigated for other conditions12. Established risk factors including body mass index (BMI), smoking 
status and GERD may be useful for risk prediction of EAC13–15 and Barrett’s esophagus16–18. However, 
existing studies have relied on age and sex matched case-control data, which may be subject to recall 
bias and ignore age and sex in improving the risk-prediction, which are strong risk factors19. An 
assessment of traditional risk factors may be useful as triage directly to endoscopy, in which case risk-
prediction for any upper gastrointestinal cancers diagnosed via endoscopy would be most informative. 
However it seems likely that EAC risk-prediction will require a multi-stage screening strategy20, of 
which some steps may be specific to EAC. 
We aimed to use prospective data from the UK biobank to develop a risk-prediction model based on 
a combination of factors widely available to clinicians that may predict risk of EAC development within 
5 years. Secondary analyses aim to develop and assess a risk-prediction model that predicts risk of all 
upper gastrointestinal cancers detected via endoscopy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
Study design 
This cohort study used prospective data from the UK Biobank, which recruited 502,640 men and 
women aged 40-69 years from one of 22 centers located across England, Scotland and Wales 
between 2006 and 201021. Approximately 9.2 million individuals registered with the National Health 
Service living within a 25-mile radius of one of the 22 centers were invited to participate. The 
response rate was 5.5% (n=503,325)22. Included in the present study were individuals aged ≥50 years 
(as upper gastrointestinal cancers are rare aged <50), without a history of cancer (excluding non-
melanoma skin cancer) at or before baseline or within 6 months following baseline (to exclude 
diagnostic delays) and with complete information on relevant risk factors.  
The UK Biobank was approved by the North West Multi-Centre Research Ethics Committee, and all 
participants provided written informed consent.  
Assessment and classification of candidate predictor variables 
Participants were asked to complete electronic touchscreen questionnaires at baseline, which 
enquired about a wide range of potential risk factors for chronic diseases, and have anthropometric 
measurements taken (Supplementary methods). Self-reported current medication use, medical 
history and surgical history were assessed via the electronic touchscreen questionnaire and were 
verified during a face-to-face interview with a trained nurse with responses matched to a coding tree, 
where possible, by a doctor.  
Candidate predictor variables widely available to clinicians, such as age and body mass index, were 
identified and categorized a priori from the literature  (Table 1)23–27. Additional candidate predictor 
variables, not thought to be widely available to clinicians, such as waist:hip ratio and others which do 
not have as strong evidence for an association with EAC, were treated separately and only included if 
they added independent predictive value (Supplementary table 1).  
 
 Outcome assessment  
The UK Biobank is regularly linked to UK cancer registry data from the Health and Social Care 
Information Centre (in England and Wales), the Scottish Cancer Registry (in Scotland) and death 
records from the UK Office of National Statistics (ONS). Cancer data was provided up until 30th 
September 2014. Newly diagnosed cancers were classified by site according to International 
Classification of Diseases, 10th version (ICD/10) and histology (ICD-O morphology codes). Primary 
EACs (ICD/10 C15, with ICD-O 8140–8573) diagnosed between 6 months (due to potential diagnostic 
delays) and 5 years from baseline was the main outcome of interest. Secondary outcomes included 
all primary upper gastrointestinal cancers (ICD/10 C15 and C16); esophageal cancer (ICD-10 C15, 
regardless of histology); gastric cancer (ICD-10 C16, regardless of histology) and; esophageal 
squamous cell carcinoma (ICD-10 C15, ICD-O 8050–8082) diagnosed between 6 months and 5 years 
from baseline. Information on tumour stage was not available. 
Statistical analysis 
Stepwise logistic regression was used to estimate factors widely available to clinicians associated with 
risk of EAC within 5 years (P<0.1).  
Points-based models were created from the coefficient-based model by dividing the coefficient of 
each variable by the smallest coefficient in the model and rounding to the nearest 0.5 to allow ease 
of calculation without a computer and easier to interpret cut-offs28. For example, the coefficient for 
men was 1.64 and the smallest coefficient in the model was 0.40 (BMI of 25-<30kg/m2), so men were 
assigned 4 points (1.64/0.40, then rounded to nearest 0.5). 
Diagnostic accuracy was quantified for the simple factor coefficient- and points- based model, 
additional factor coefficient- and points- based model using the area under the receiver operating 
characteristic (AUROC) curve with 95% confidence interval (CI). An internally validated AUROC was 
calculated using bootstrap methods described by Steyerberg et al29 accounting for optimism in model 
selection (including the stepwise selection procedure) and performance. Goodness-of-fit was assessed 
using Hosmer-Lemeshow tests and calibration curves. 
 AUROC, sensitivity, specificity, Youden’s index (sensitivity + specificity -1), risk of EAC within 5 years 
(equivalent to positive predictive value) and number of referrals for additional screens per cancer 
correctly predicted were assessed for individuals above each points based cut-off threshold. 
To assess if a more complex model increased model performance (AUROC), additional factors, not 
widely available to clinicians or which may require additional examination, were added to the initial 
model in turn (excluding individuals with missing data) then with all factors significant at P<0.1 added 
to a stepwise selection model. 
A priori sensitivity/secondary analyses assessed the AUROC and stepwise model selection when:  
 including individuals with a prior history of non-upper GI cancers;  
 conducting multiple imputation for missing variables (using ten imputations and combined using 
Rubin’s rules);   
 using different cancer follow-up periods;  
 using different age periods;  
 using different categories for smoking, BMI and separate variables for each oesophageal 
condition; 
 stratifying by age, sex, BMI, smoking history and esophageal condition status at baseline to check 
model performance for importance patient subgroups and;  
 excluding individuals who reported a history of Barrett’s esophagus or esophagitis as these may 
already be undergoing endoscopic surveillance.  
Further secondary analyses assessed the discriminative ability of the risk-prediction model identified 
in the primary analyses for total upper gastrointestinal cancer, as the tool could be used as triage to 
endoscopy which could detect all types of gastric and esophageal cancers. For comparison we also 
used stepwise logistic regression to estimate factors widely available to clinicians associated with risk 
of total upper gastrointestinal cancer within 5 years (P<0.1) and assessed the discriminative ability of 
a new points- based model. 
Analyses were conducted using Stata/SE statistical software (version 14.1, College Station, TX, USA). 
Results 
Participants 
There were 502,640 participants in the UK Biobank, of whom 117,891 (23.5%) were excluded as they 
were aged under 50 years, 30,665 (6.1%) were excluded due to a history of cancer (or cancer within 6 
months of baseline), and 4,060 were excluded due to missing data (0.8%).  This left 355,034 (70.7%) 
for inclusion in the final study cohort, among whom 220 individuals were diagnosed with EAC within 
5 years. Individuals diagnosed with EAC were more likely to be older, male, smoke (current or former), 
have a higher BMI, have an existing esophageal or gastric condition, diabetes or hypertension, be 
below UK average height for their sex and use NSAIDs, statins or asthma inhalers (Table 1). Mean 
follow-up time was 4.8 (standard deviation 0.6) years. 
Non-participants 
Individuals excluded due to incomplete data for some of the candidate predictor variables tended to 
be older, male, smoke (current), obese, tall, have an existing esophageal or gastric condition, diabetes 
or hypertension, or use NSAIDs, statins or Asthma inhalers. 
EAC risk-prediction model: coefficient-based model 
After applying the multi-phase stepwise procedure, the final coefficient-based model for predicting 
EAC development within 5 years included age at baseline, sex, BMI, smoking status and history of 
diagnosis or treatment for esophageal conditions (Table 2). This model had good discrimination, with 
an AUROC of 0.80 (95% CI 0.77-0.82, see Figure 1A). We found little evidence of overfitting in internal 
validation where the model showed equally good discriminatory ability (internally validated AUROC 
of 0.79). The performance of the model was statistically good by the goodness-of-fit test (Hosmer-
Lemeshow test, chi2 statistic=6.58, p=0.58), and the calibration curve (Figure 1B). 
EAC risk-prediction model: points-based model 
A points-based model assigned additional points based on age (55-60 years: 1.5; 60-65 years: 2.5; 65+ 
years: 3.5), sex (males: 4), smoking status (former: 2; current: 3.5), BMI (>25-30: 1; 30-<35: 1.5; 35+: 
2.5) and history of esophageal conditions or treatment (1.5) (Table 2 & Figure 2). The AUROC for the 
points-based model was similar (0.80, 95% CI 0.77-0.82) to that of the coefficient-based model. The 
discriminative performances at each points-based cut-off threshold are provided in Table 3. A cut-off 
threshold of 8+ points with the highest Youden’s index (0.48), had a sensitivity of 77.5%, a specificity 
of 70.5%, a positive predictive value of 0.16% (Figure 1C) and would mean 612 referrals for further 
screening for every EAC predicted, with 29.5% (104,723 individuals) of the cohort (59.7% of men and 
3.5% of women) deemed high-risk. Of the individuals above the 8 point cut-off threshold, 76.4% 
(79,970 individuals) had not reported a prior esophageal medical history. 
Sensitivity analyses  
No improvement in AUROC was apparent when additional variables not widely available to clinicians 
such as smoking status by pack-years and abdominal obesity were added to the model 
(Supplementary table 2). The AUROC was similar in various sensitivity analyses, including when 
separating oesophageal conditions by type and after multiple imputation (Supplementary table 3-4). 
Upper gastrointestinal cancers (gastric and esophageal cancers) 
The factors selected in the model for upper gastrointestinal cancer (gastric or esophageal cancers) 
within 5 years was the same as the model selected for EAC (age, sex, BMI, smoking status, history of 
esophageal conditions or treatments). The AUROC for predicting any upper gastrointestinal cancer of 
0.74 (95% CI 0.72-0.76) or for predicting risk of any gastric cancer within 5 years of 0.72 (95% CI 0.69-
0.76) were lower than that observed for EAC. The AUROC for predicting risk of esophageal cancer of 
any histological type within 5 years was 0.76 (95% CI 0.73-0.79) (Supplementary Table 3).  
Due to similarity in structure, for simplicity, we report results using the EAC points system. The 8-point 
cut-off again had the highest AUROC for any upper gastrointestinal cancer (0.68, 95% CI 0.66-0.71), 
sensitivity was 66.3%, specificity was 70.5% and positive predictive value was 0.31% cancer. This would 
represent 312 referrals for screening for every upper gastrointestinal cancer predicted (compared 
with 612 for EAC alone) (Supplementary table 5). 
DISCUSSION 
This cohort study using prospective data from the UK Biobank identified how combining established 
risk factors can aid risk-prediction of EAC. The risk-predictors identified included age at baseline, sex, 
tobacco smoking status, BMI and a history of esophageal conditions or treatments including GERD 
(Table 2). The model was well calibrated and the discriminative performance was unchanged after 
internal validation using bootstrapping.  
The factors included in the risk-prediction model are broadly consistent with factors identified in risk-
prediction models of Barrett’s esophagus and EAC using case-control methodology13,14,16,18, which 
included BMI, smoking status and esophageal conditions. However, the association between previous 
esophageal conditions and EAC risk was weaker than in previous studies13,14, perhaps due to the lack 
of a specific question on gastroesophageal reflux symptoms or the minimization of recall bias in the 
current study. This indicates that the findings are robust to methodological differences. Other 
potential risk-factors for EAC, I.e. NSAIDs were not confirmed to have utility in risk-prediction, though 
this does not exclude a role for such factors in disease etiology.  The discriminative ability of the model 
was similar after accounting for optimism using bootstrap samples, and in analyses stratified by age, 
BMI, smoking history and a history of esophageal conditions or treatments, suggesting the finding may 
be robust to changing characteristics of the model or population. The discriminative ability was lower 
when stratified by sex, which highlights the importance of sex as a predictive factor.  
Additional factors tested, that may not be so widely available to clinicians and may require face-to-
face assessment, I.e. waist:hip ratio, did not improve the model performance in terms of AUROC. 
Therefore, it may not be necessary to make the additional effort it may take clinicians to collect 
information on these factors.  Thus, the risk-prediction model could be used to develop an automated 
algorithm linked to clinical records, to flag high-risk individuals to clinicians for screening or lifestyle 
advice, which could lower the cost and time of administering the test. 
Despite low cost of administration, the absolute five-year risk of EAC in individuals above the 8-point 
cut-off threshold (162.3 per 100,000) is still fairly low which may limit cost-effectiveness of referring 
these individuals for further screening. This is especially true if the test is used to triage directly to 
endoscopy, even when considering the higher absolute five-year risk of any upper gastrointestinal 
cancer that can be detected by endoscopy in individuals above this threshold (313.20 per 100,000). 
Nevertheless, it could be argued that these estimates are higher than the estimated absolute 5-year 
incidence in GERD patients of ~100 per 100,000 in a recent review 30, in whom guidelines recommend 
referral for endoscopy7.  
This study focused on a risk-prediction tool for triage to an intermediate step, such as blood test, 
breath tests, Cytosponge31 or capsule endoscopies32. These additional triage steps could improve 
specificity, and better identify high-risk individuals in whom endoscopic screening may be cost-
effective. Future studies should assess whether blood-based biomarkers could further enhance the 
specificity of this clinical risk prediction model, as has been demonstrated for Barrett’s esophagus risk-
prediction15,17. Full health economic modelling would be required to assess the cost-effectiveness of 
changes to screening practices. 
Strengths & limitations 
A main strength is the cohort design using prospective data for this relatively rare cancer, which 
minimized recall bias and allowed the predictive value of age and sex to be estimated (which are 
typically matched on within case-control studies).  
The self-report medical history, without a specific question on gastroesophageal reflux symptoms, 
lowers the accuracy of reporting of GERD history. The medication use was self-reported which could 
limit the accuracy33. However, the follow-up interview with a trained health professional should 
reduce misreporting  of medical history or medication use. We also did not have information on 
degree or duration of medication use for reflux symptoms which added predictive value to a similar 
model in a previous study14. The generalisability of the UK Biobank to the general population has been 
criticised due to the healthy participant effect22. Further studies could validate the findings of the 
current study using electronic clinical record databases, where symptom history may be better 
captured, as this would better reflect the level of information available to clinicians and be more 
generalizable. 
The medical history data provided information on Barrett’s esophagus or esophagitis, rather than on 
either condition alone. Individuals with Barrett’s esophagus or esophagitis remained in the primary 
analyses, as esophagitis offers a potentially useful source of EAC risk prediction. A sensitivity analysis 
in which individuals with Barrett’s esophagus or esophagitis were excluded did not alter the results, 
suggesting any potential detection bias due to endoscopic surveillance in some Barrett’s esophagus 
patients was minimal.  
Conclusion 
In summary, a list of established risk factors including age, sex, BMI, smoking status and esophageal 
conditions could aid risk-prediction of EAC. These factors are consistent with previous risk-prediction 
studies, though the points attributed and positive predictive values for specific cut offs require 
external validation.  
 
 
 
 
 
 
 
 
Table and Figure legends 
Table 1. Characteristics of study population in terms of candidate predictor variables at the baseline 
assessment visit, who did or did not develop oEAC within 5 years. 
Table 2. Risk factors associated with oEAC in a stepwise logistic regression and the points assigned 
for the points based model. 
Table 3. Statistics for the performance of a points-based oEAC risk-prediction model at different points 
based cut-offs. 
Figure 1. (A) Receiver operating characteristic (ROC) curve for the based model for predicting risk of 
EAC within 5 years; (B) Hosmer-Lemeshow calibration plot: Observed versus predicted proportion, 
based upon risk score, of individuals with EAC within 5 years, and; (C) Cumulative proportion 
developing EAC from 6 months to five years following baseline based upon risk score (<8 points 
versus 8+ points). 
Figure 2. Nomogram for assigning points (out of a total of 15) to help identify individuals at a higher 
risk of oEAC within 5-years. 
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